No Data
No Data
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small
Express News | Zentalis Pharmaceuticals Inc -on and Effective May 24, Board Increased Its Size From Six to Seven Directors
Express News | Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.d., to Board of Directors
Zentalis Says Azenosertib Combo Shows 'Promise' in Relapsed Osteosarcoma Trial
Zentalis Pharmaceuticals (ZNTL) said final results from a phase 1 trial of azenosertib plus gemcitabine in relapsed or refractory osteosarcoma resulted in clinically meaningful increase in event-free
Zentalis Pharmaceuticals to Present Promising Results From Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced the presentation of final results from a Phase 1 trial of azenosertib and gemcitabine in relapsed or refractory (R/R) osteosarcoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
No Data